OncoMatch/Leukemia — Chronic Myeloid (CML)/ABL1 kinase domain mutation
Leukemia — Chronic Myeloid (CML)ABL1 kinase domain mutation Clinical Trials
ABL1 kinase domain mutations — most notably T315I — are the primary mechanism of TKI resistance in CML, conferring varying degrees of resistance to first-, second-, and third-generation inhibitors. The T315I 'gatekeeper' mutation is uniquely resistant to all ATP-competitive TKIs except ponatinib; asciminib (STAMP inhibitor binding the myristoyl pocket) is active against T315I. Trials investigate mutation-specific treatment sequencing, asciminib combinations, and novel allosteric ABL1 inhibitors.
Top recruiting ABL1 kinase domain mutation Leukemia — Chronic Myeloid (CML) trials
Ranked by phase and US site count. See all 19 trials matched to your profile →
A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs
Il-Yang Pharm. Co., Ltd.
Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune System
Poitiers University Hospital
A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)
Terns, Inc.
KRT-232 and TKI Study in Chronic Myeloid Leukemia
Kartos Therapeutics, Inc.
ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase
M.D. Anderson Cancer Center
Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Browse other molecular targets with active Leukemia — Chronic Myeloid (CML) trials.